Novel diagnostic biomarkers for pancreatic cancer: assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA.

MLA

Hongsik Kim, et al. “Novel Diagnostic Biomarkers for Pancreatic Cancer: Assessing Methylation Status with Epigenetic-Specific Peptide Nucleic Acid and KRAS Mutation in Cell-Free DNA.” Frontiers in Oncology, July 2024, pp. 1–9. EBSCOhost, https://doi.org/10.3389/fonc.2024.1395473.

APA

Hongsik Kim, Jinah Chu, In-Gu Do, Yong-Pyo Lee, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Chinbayar Batochir, Eunji Jo, Kyo Rim Kim, & Hye Sook Han. (2024). Novel diagnostic biomarkers for pancreatic cancer: assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA. Frontiers in Oncology, 1–9. https://doi.org/10.3389/fonc.2024.1395473

Chicago

Hongsik Kim, Jinah Chu, In-Gu Do, Yong-Pyo Lee, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, et al. 2024. “Novel Diagnostic Biomarkers for Pancreatic Cancer: Assessing Methylation Status with Epigenetic-Specific Peptide Nucleic Acid and KRAS Mutation in Cell-Free DNA.” Frontiers in Oncology, July, 1–9. doi:10.3389/fonc.2024.1395473.